{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:35:15Z","timestamp":1790976915977,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020147","name":"European Network for Rare Adult Solid Cancers","doi-asserted-by":"publisher","award":["EC 739521"],"award-info":[{"award-number":["EC 739521"]}],"id":[{"id":"10.13039\/501100020147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022238","name":"LabEx DEvweCAN","doi-asserted-by":"publisher","award":["ANR-10-LABX-0061"],"award-info":[{"award-number":["ANR-10-LABX-0061"]}],"id":[{"id":"10.13039\/501100022238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004830","name":"Siemens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004830","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001472","name":"Singapore Police Force","doi-asserted-by":"publisher","award":["INCA-DGOS-INSERM 12563"],"award-info":[{"award-number":["INCA-DGOS-INSERM 12563"]}],"id":[{"id":"10.13039\/501100001472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jtho.2019.08.2506","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T18:42:49Z","timestamp":1569004969000},"page":"29-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach"],"prefix":"10.1016","volume":"15","author":[{"given":"Andrew G.","family":"Nicholson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu R.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Remy-Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Samuel G.","family":"Armato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette","family":"Fernandez-Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Alcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Attanoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Brcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Butnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian R.","family":"Chirieac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Courtiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"De Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frauenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lantuejoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Perol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Roggli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tirode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Tazelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"van Schil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Vignaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Weynand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Lang-Lazdunski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Cree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau-Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2019.08.2506_bib1","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","year":"2015"},{"key":"10.1016\/j.jtho.2019.08.2506_bib2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"Rice","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib5","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/01.pas.0000165529.78945.dc","article-title":"Localized malignant mesothelioma","volume":"29","author":"Allen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib6","article-title":"Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Interest Group","author":"Marchevsky","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib7","article-title":"Molecular characterization of localized pleural mesothelioma","author":"Hung","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/jclinpath-2016-203993","article-title":"Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma","volume":"70","author":"Alchami","year":"2017","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Kadota","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/modpathol.2012.39","article-title":"Pleomorphic mesothelioma: report of 10 cases","volume":"25","author":"Ordonez","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/modpathol.3800543","article-title":"Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases","volume":"19","author":"Ordonez","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/his.12807","article-title":"Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma","volume":"68","author":"Krasinskas","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2019.08.2506_bib13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center","volume":"13","author":"Galateau Salle","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/PAS.0b013e31802baad7","article-title":"Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases","volume":"31","author":"Galateau-Salle","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/01913128809064207","article-title":"Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma","volume":"12","author":"Henderson","year":"1988","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib16","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.jtho.2019.08.2506_bib17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00000478-200404000-00013","article-title":"Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases","volume":"28","author":"Galateau-Salle","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/PAS.0000000000000200","article-title":"Well-differentiated papillary mesothelioma with invasive foci","volume":"38","author":"Churg","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41379-018-0127-2","article-title":"Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42","volume":"32","author":"Stevers","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.anndiagpath.2018.10.012","article-title":"Well-differentiated papillary mesothelioma: a 17-year single institution experience with a series of 75 cases","volume":"38","author":"Sun","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2017.10.036","article-title":"Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study","volume":"72","author":"Xing","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/PAS.0000000000000935","article-title":"PAX8 Expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma","volume":"41","author":"Chapel","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2019.08.2506_bib24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2019.08.2506_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/modpathol.2009.180","article-title":"Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases","volume":"23","author":"Klebe","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib26","first-page":"151","article-title":"The concept of mesothelioma in situ: implications for diagnosis and histogenesis","volume":"9","author":"Whitaker","year":"1992","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2019.08.2506_bib28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","article-title":"BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma","volume":"60","author":"McGregor","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib30","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.21037\/jtd.2017.10.88","article-title":"Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review","volume":"10","author":"Bruno","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2019.08.2506_bib31","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2019.08.2506_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/dc.24061","article-title":"The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology","volume":"47","author":"Hatem","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/dc.23837","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions","volume":"46","author":"Cozzi","year":"2018","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol Int"},{"key":"10.1016\/j.jtho.2019.08.2506_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/dc.23491","article-title":"BAP1 immunostain and CDKN2A (p16) FISH analysis: clinical applicability for the diagnosis of malignant mesothelioma in effusions","volume":"44","author":"Walts","year":"2016","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2019.08.2506_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.2506_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2018.09.019","article-title":"A\u00a0combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis","volume":"125","author":"Kinoshita","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.2506_bib40","first-page":"750","article-title":"Comparison of MTAP immunohistochemsitry (IHC) with P16\/CDKN2A deletion\/loss and utility of MTAP and BAP1 IHC in the diagnosis of malignant pleural mesothelioma (MPM)","volume":"98","author":"Shahi","year":"2018","journal-title":"Lab Invest"},{"key":"10.1016\/j.jtho.2019.08.2506_bib41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/his.13468","article-title":"Malignant mesothelioma in situ","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2019.08.2506_bib42","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","author":"Churg","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A\u00a0nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib45","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jtho.2018.07.002","article-title":"Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal","volume":"13","author":"Pelosi","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2012.105","article-title":"Deciduoid mesothelioma: report of 21 cases with review of the literature","volume":"25","author":"Ordonez","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00000478-200002000-00015","article-title":"Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females","volume":"24","author":"Shanks","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best practices recommendations for diagnostic immunohistochemistry in lung cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib49","doi-asserted-by":"crossref","first-page":"1310478","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.jtho.2019.08.2506_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-015-0040-5","article-title":"BAP1 hereditary cancer predisposition syndrome: a case report and review of literature","volume":"3","author":"Klebe","year":"2015","journal-title":"Biomark Res"},{"key":"10.1016\/j.jtho.2019.08.2506_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2019.08.2506_bib53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib54","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib56","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"Gordon","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2019.08.2506_bib57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2019.08.2506_bib58","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.08.2506_bib59","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-85184-4","article-title":"V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant mesothelioma","author":"Muller","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-017-3375-5","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2019.08.2506_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32416","article-title":"Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma","author":"Chirieac","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2019.08.2506_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.semtcvs.2009.06.011","article-title":"Current trends in radiologic management of malignant pleural mesothelioma","volume":"21","author":"Gill","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2019.08.2506_bib63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"Radiographics"},{"key":"10.1016\/j.jtho.2019.08.2506_bib64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.11.010","article-title":"The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy","volume":"103","author":"Tsim","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.2506_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/sonc.2002.30228","article-title":"The role of imaging in malignant pleural mesothelioma","volume":"29","author":"Marom","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.mric.2008.03.004","article-title":"MR imaging of benign and malignant pleural disease","volume":"16","author":"Gill","year":"2008","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"10.1016\/j.jtho.2019.08.2506_bib67","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1148\/radiol.12110872","article-title":"Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging\u2014initial experience","volume":"263","author":"Coolen","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2019.08.2506_bib68","doi-asserted-by":"crossref","first-page":"W125","DOI":"10.2214\/AJR.09.3519","article-title":"Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes","volume":"195","author":"Gill","year":"2010","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2018.01.014","article-title":"Early contrast enhancement: a novel magnetic resonance imaging biomarker of pleural malignancy","volume":"118","author":"Tsim","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.2506_bib70","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1378\/chest.129.6.1570","article-title":"Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome","volume":"129","author":"Giesel","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2019.08.2506_bib71","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.acra.2007.12.014","article-title":"Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34)","volume":"15","author":"Giesel","year":"2008","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib72","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00330-018-5533-9","article-title":"Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study","volume":"29","author":"Gudmundsson","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib73","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cpet.2011.04.001","article-title":"Multimodality imaging review of malignant pleural mesothelioma diagnosis and staging","volume":"6","author":"Gerbaudo","year":"2011","journal-title":"PET Clin"},{"key":"10.1016\/j.jtho.2019.08.2506_bib74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djx175","article-title":"Quantitative clinical staging for patients with malignant pleural mesothelioma","volume":"110","author":"Gill","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2019.08.2506_bib75","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American multicenter volumetric CT study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib76","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01428-2016","article-title":"Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma","volume":"49","author":"de Perrot","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2019.08.2506_bib77","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib78","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/annonc\/mds535","article-title":"Disease volumes as a marker for patient response in malignant pleural mesothelioma","volume":"24","author":"Labby","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib79","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","article-title":"Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma","volume":"115","author":"Pass","year":"1998","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2019.08.2506_bib80","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jtcvs.2004.10.034","article-title":"Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications","volume":"129","author":"Erasmus","year":"2005","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2019.08.2506_bib81","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib82","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib83","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jtho.2018.05.003","article-title":"Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): a step forward in a long race","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib84","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A\u00a0novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib86","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib87","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib88","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib89","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2019.08.2506_bib90","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2019.08.2506_bib91","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib92","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cllc.2017.03.010","article-title":"LUME-Meso: design and rationale of the phase III part of a placebo-controlled study of nintedanib and pemetrexed\/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma","volume":"18","author":"Scagliotti","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.2506_bib93","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2019.08.2506_bib94","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of immune checkpoint inhibitors in mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib96","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2019.08.2506_bib97","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib98","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib99","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2019.08.2506_bib100","article-title":"A\u00a0phase II study of nivolumab: a Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)","volume":"11","author":"Goto","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib101","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2019.08.2506_bib102","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients with previously treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib103","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"suppl","key":"10.1016\/j.jtho.2019.08.2506_bib104","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/S1556-0864(18)30486-6","article-title":"Nintedanib\u00a0+ pemetrexed\/cisplatin in malignant pleural mesothelioma (MPM): phase II biomarker data from the LUME Meso study","volume":"13","author":"Pavlakis","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2019.08.2506_bib106","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2019.08.2506_bib107","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","article-title":"Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation","volume":"36","author":"Zauderer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.2506_bib108","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2019.08.2506_bib109","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2019.08.2506_bib110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.21037\/atm.2017.03.81","article-title":"Novel immunotherapy clinical trials in malignant pleural mesothelioma","volume":"5","author":"Tano","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2019.08.2506_bib111","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/imt.16.4","article-title":"Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy","volume":"8","author":"O'Hara","year":"2016","journal-title":"Immunotherapy"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419332320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419332320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:42:23Z","timestamp":1761561743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086419332320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1556086419332320"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2019.08.2506","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.08.2506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}